Halma began as a Sri Lankan tea estate in 1894 and is now a ~£17.6bn FTSE 100 group that buys 5–15 niche safety, environmental and health instrument businesses a year and lets them run themselves — a discipline that has produced 46 straight years of ≥5% dividend growth.

In FY2024/25 (year ended 31 March 2025) Halma posted record revenue of £2,248.1m (+11%, +9% organic) and adjusted EBIT of £486.3m (+15%), its 46th consecutive year of ≥5% dividend growth and 22nd straight year of profit growth[1]. Then H1 FY2025/26 accelerated — organic growth jumped to 16.7%, lifting FY2026 guidance to mid-teens[23][37]. The open question is not whether Halma is a good business; it is whether a model built on patient, small bolt-ons can keep compounding at this pace — and whether the AI-photonics surge now driving it is a structural tailwind or a single-customer risk. This site lays out both cases and leaves the verdict to you.

The decisive questions

Each links to the section that lays out the evidence on both sides.

The compounding trajectory that frames the debate

Halma grew revenue from roughly £1.32bn in FY2021 to a record £2.25bn in FY2025, and H1 FY2026 plus the raised guide imply roughly £2.55bn for the full year (an estimate, not a reported figure)[1][23]. The shape — steady compounding, then a sharp acceleration — is both the bull case and the thing the bears watch most closely.

Halma traces to an 1894 Sri Lankan tea company, pivoted to an investment holding company in 1956, listed in London in 1972, and found its identity with the 1984 Apollo Fire Detectors acquisition that moved it into safety[4]. It entered the FTSE 100 in December 2017 and today employs roughly 8,000 people across 45+ operating companies in 20+ countries[7][3].

What Halma is today

Halma describes itself through a single purpose — to “grow a safer, cleaner, healthier future for everyone, every day”[38] — and operates as a decentralised serial acquirer: a portfolio of more than 45 niche businesses across 20+ countries, acquiring roughly 10–15 (in practice more often 5–7) safety, environmental and health businesses a year and largely leaving them to run themselves[3]. FY2025 net income was about £296.4m[7].

The people and the philosophy

The modern company was shaped by David Barber, who co-founded it with Mike Arthur, served as CEO for over twenty years and as Chairman until 2003[5]. His framing — build slowly and carefully, take the long view — still describes the model. Marc Ronchettibecame Group Chief Executive in 2023 after Andrew Williams' 18-year tenure (2005–2023); Dame Louise Makin chairs the board[6].

A long arc, dated

Halma organises itself into three market-defined sectors — Safety, Environmental & Analysis, and Healthcare— whose demand it ties to structural megatrends: climate and pollution, rising regulation, ageing populations and pressure on life-critical resources[8][35]. In FY2025 those sectors grew very unevenly: Environmental & Analysis +19% organic, Safety +7.7%, Healthcare just +0.3%[9].

The portfolio mix

Safety is the largest revenue base, Environmental & Analysis the fastest-growing (lifted by photonics), and Healthcare the smallest and slowest. The split below is approximate FY2025 revenue by sector.

Growth is concentrated, not even

The dispersion is the story. Environmental & Analysis grew organic revenue ~19% and adjusted profit +25.4%, while Healthcare was effectively flat at +0.3% organic[9]. A diversified portfolio is supposed to smooth results — here, one sector is carrying the others.

The megatrend case — and its limits

Halma frames demand around long-run drivers — urbanisation, ageing populations, tightening environmental regulation and demand on life-critical resources — arguing this makes revenue resilient across cycles[35][8]. The thesis is plausible and the company's own materials, plus third-party commentary, lean on it heavily — but it is also the kind of broad narrative every diversified industrial tells, and it did not prevent Halma's own earlier organic-growth slowdown.

Halma's stated model is a roughly 50% organic / 50% acquisitive growth engine with a long-term ambition to double earnings per share every five years, funded by reinvestment and disciplined bolt-on M&A[10]. It targets high returns on invested capital and a 19–23% EBIT-margin band; in FY2025 it delivered 15.0% ROTIC, 112% cash conversionand net debt at just 0.97× EBITDA[11].

The flywheel

The model has three reinforcing parts. First, Halma buys niche, highly-engineered businessesthat lead small, fragmented markets — products with strong margins, recurring demand and low customer concentration[16]. Second, it preserves local management autonomy, aiming for “start-up agility with multinational scale,” while a central team supplies capital, talent and M&A capability. Third, it recycles the resulting cash into more organic R&D (£108.4m, 4.8% of revenue in FY2025) and more acquisitions[11]. Since 1983 it has completed on the order of 150+ acquisitions(one count cites 154), supported by a dedicated 20+-person M&A team[34].

The numbers behind the model

Halma frames internal KPIs around a long-term return on total invested capital target near 12%, ~20%+ net margins per sector, and a historic ambition of ~16% annual profit-before-tax growth (split 50/50 organic and acquisitive)[12]. FY2025 adjusted EPS rose 14% to 94.23p and the total dividend rose 7% to 23.12p[11]— the dividend cadence that anchors the 46-year record.

Halma sits in a small, closely-watched cohort of niche-acquisition compounders — Constellation Software, Danaher, Diploma, Judges Scientific, Lifco and Addtech— that built “Swedish-style” models of buying niche industrial and scientific businesses with recurring revenue and low customer concentration[13]. Within its product niches direct rivalry is limited; the fiercer competition is at the M&A layer, where the same buyers bid up the same assets.

Two layers of competition

At the product level, Halma's operating companies often hold leading positions in small, regulated, certification-heavy niches — which deters new entrants and dampens direct rivalry. But for growth Halma competes in a crowded acquisition market against other serial acquirers and private equity chasing the same businesses. The Five-Forces read below treats both layers.

Where Halma sits in the cohort

The peers differ less in what they buy than in how they scale. Constellation Software has reached ~100 acquisitions a year by pushing M&A down to its operating units; Danaher is far larger and runs the systematic Danaher Business System to improve businesses post-acquisition — a group-wide operating capability commentators say Halma lacks[14]. Diploma is a close UK analogue at about half Halma's size[33]. The map places the cohort by acquisition velocity (horizontal) against reliance on organic compounding (vertical) — illustrative placements with the basis on hover.

The valuation gap

On forward earnings, Halma carries the richest multiple in the set: roughly 39×versus Diploma ~28×, Danaher ~24× and Honeywell ~20–21× (mid-2026 third-party estimates)[15]. That premium is the crux of the valuation debate — the market pays up for Halma's quality and growth, but leaves less margin for error than its peers.

This is the question the whole study turns on. Halma's defenders point to a ~15% 20-year free-cash-flow CAGR and a multi-decade dividend record as proof the decentralised model durably compounds[18]. Critics counter that the model has scaling limits: most serial acquirers never break ~20 deals a year, Halma lacks a Danaher-style improvement system, and moving toward a layered “platform” structure can dull the very opco incentives that made it work — implying it may compound free cash flow at ~10% rather than match Constellation[17][19].

The case that the moat is real

Halma's edge, supporters argue, is buying niche, highly-engineered businesses with strong positions in small markets and then preserving local autonomy — “start-up agility with multinational scale” — historically at attractive prices (~8× EBIT in 2003–2013)[16]. The long-run numbers back the durability claim: a reported ~15% free-cash-flow CAGR over 20 years and a ~5% multi-decade dividend-per-share CAGR[18].

The case that the model is hitting limits

The skeptical view, articulated most sharply by In Practise, is twofold. First, scaling: most acquirers never break the 20-deals-a-year level, so absent organisational change Halma is more likely to compound free cash flow at ~10% than to reach Constellation-level returns[19]. Second, incentives and capability: as Halma layers sector structures over its opcos, removing full P&L ownership from operating leaders “may create perverse incentives by reducing the agency of those running the operating company,” and without a DBS-style system the group must rely heavily on the “quality of assets purchased on day 1” rather than on transforming them[17].

The signal to watch: bigger deals

One concrete tell is deal size. In December 2025 Halma acquired E2S Group (industrial warning-signal devices, ~£44m revenue) for £230m(~$307m) — a notably large deal versus its historic average of roughly 4.8 bolt-ons a year[31]. Bigger acquisitions can accelerate growth, but they raise the average multiple paid and the integration stakes — exactly the roll-up pressures the critics flag.

In H1 FY2025/26 a single, undisclosed hyperscaler accounted for 19% of group revenue, up from 14% a year earlier, driven by Avo Photonics supplying optical components for AI data centres[20]. Photonics added roughly 8 percentage pointsto group organic growth, expanding ~55–60% organically[20]. The same engine that powered a guidance upgrade and the share re-rating is also the largest single-customer concentration in Halma's history.

The acceleration

Group organic revenue growth jumped from roughly 5% in H1 FY2025 to 16.7%in H1 FY2026 — with photonics contributing about half of that step-up[23][20]. It is the single clearest driver of the FY2026 guidance raise to mid-teens organic growth[37].

‘Not just a photonics story’ — the bull rebuttal

Sell-side analysts pushed back on the idea that Halma is now a one-trick AI proxy. UBS and Stifel argued the H1 beat was “not just a photonics story”: Environmental & Analysis excluding photonics grew ~18% organically, Healthcare +7% and Safety +6%[21]. UBS raised its target to 4,100p; Stifel called the ~31× FY2026 multiple “full” but said the performance “fully justifies a substantial premium”[21].

The concentration that warrants attention

The other side of the same fact: Avo Photonics has a ~10-year relationship with one undisclosed hyperscaler, and that single account scaled to ~19–20% of group sales[22]. The backdrop is hyperscaler capex — Alphabet, Amazon, Meta and Microsoft invested ~US$350bn in 2025, forecast to rise toward ~US$575bn in 2026 (+64%) as AI data centres shift interconnects from copper to optics[36]. That is a powerful tailwind and a single-customer, single-end-market dependency that could reverse with the capex cycle.

FY2025 was a record: revenue £2,248.1m (+11%, +9% organic), adjusted EBIT £486.3m(+15%) at a 21.6% margin[1]. H1 FY2025/26 then accelerated — revenue £1,237.4m(+15.2%, +16.7% organic), adjusted EBIT +26.7% at a 22.8% margin, statutory PBT +39.0% — prompting a guidance raise to mid-teens organic growth and ~22% margin[23][37]. Shares rose ~10% on the November 2025 results[24].

The revenue trajectory

Steady compounding to a £2.25bn FY2025 record, with H1 FY2026 and the raised guide implying roughly £2.55bn for the full year — an estimate, not a reported figure[23][37].

Capital discipline

The growth has not come at the cost of the balance sheet. FY2025 ROTIC was 15.0% (+60bps), cash conversion 112%, net debt just 0.97×EBITDA, and R&D £108.4m (4.8% of revenue)[11]. Adjusted EPS rose 14% to 94.23p; the total dividend rose 7% to 23.12p — the 46th straight year of ≥5% dividend growth[11][1]. On a trailing-twelve-month basis to early June 2026, revenue was ~£2.41bn and net income ~£347m, with ROE ~18.6% and ROIC ~14.3%[32].

The M&A cadence

Acquisitions remain the other growth engine: FY2025 saw seven acquisitions for up to £157mmaximum consideration, and H1 FY2026 deployed £129m across two deals[25]— before the £230m E2S deal in December 2025 stretched the cheque size further[31].

Against its peers Halma is a mid-sized, high-return, premium-priced niche acquirer. It is larger and faster-growing than UK analogue Diploma, far smaller and faster than Danaher, and pricier than all of them on forward earnings (~39× vs. Diploma ~28×, Danaher ~24×, Honeywell ~21×)[15][33]. The recurring analyst caveat: even “incredible businesses” like Halma and Diploma have not matched Constellation Software's unit economics at scale[40].

The comparables table

The valuation premium, visualised

Halma carries the richest forward multiple in the cohort — the market's vote on its quality and growth, and the smallest cushion if growth normalises[15].

The scaling caveat

The cohort's most-cited critique is that Constellation Software's capital deployment is hard to replicate. Judges Scientific, a smaller niche acquirer buying at a strict 3–6× EBIT, has returned roughly 100× since 2006 — but analysts flag both Judges and SDI face scaling hurdles beyond ~25 companies, and the same scaling question hangs over Halma[27].

Consolidation in the niche-instrument space is also live: Diploma trades on a Buy consensus, and UK instrumentation peer Spectrisagreed a recommended cash takeover by Advent in 2025 — evidence both of peer demand and of how prized these assets have become[33].

Four risks recur in the skeptical literature: valuation(a forward P/E ~39–40× that some analyses call overvalued[29]), cyclicality (Halma has had a visible organic slowdown[28]), portfolio dispersion (Healthcare was flat at +0.3% organic in FY2025[39]), and acquisition discipline(a broker Sell on the Brownline deal at the top of Halma's price range with strategic-fit questions[30]). To these the photonics section adds single-customer concentration.

Valuation

Skeptics argue Halma is richly priced. One independent analysis called it overvalued by ~32% versus intrinsic value, citing a forward P/E around or above 40×— well above the FTSE 100 average and its peers — leaving little room if growth normalises to high-single digits[29]. Bulls counter that record results “fully justify a substantial premium”[21]; the disagreement is about price, not quality.

Cyclicality

The model is not immune to end-market cycles. Halma has been through softer half-year updates — one where weaker Healthcare trading amid customer destockingand weak China meant the print “failed to impress the market,” with stronger Safety and Environmental & Analysis only partly offsetting it[28]. The same destocking dynamic reappears in Healthcare's flat FY2025 organic growth (below)[39]. The current acceleration is real, but so were the prior soft patches.

Portfolio dispersion

Not every part of the portfolio compounds evenly. Healthcare — Halma's smallest sector — grew organic revenue and profit just +0.3% in FY2025[39]. Diversification cuts both ways: it smooths shocks, but it also means weaker sectors dilute the strong ones.

Acquisition discipline at the margin

As Halma writes larger cheques, deal scrutiny rises. A broker issued a Sellciting high valuation and the Brownline acquisition being at the top of Halma's typical price range, with strategic-fit questions (horizontal gas drilling versus its renewable/clean-energy framing)[30]. The £230m E2S deal similarly signals a shift toward larger, pricier acquisitions[31].

Method

Research proceeded by fan-out web search across the question areas below and direct fetching of primary and reputable secondary sources. Halma's own newsroom releases — the FY2024/25 full-year results and the H1 FY2025/26 interim results — were preferred for all financial figures, followed by reputable secondary press and named analysts (Proactive, Investing.com, In Practise, MatrixBCG), with market data from stockanalysis.com / GuruFocus / Alpha Spread treated as third-party estimates. Every URL cited on the Sourcespage was opened and read during research; no link was reconstructed from memory. Each claim was transcribed into a structured manifest tagging it with a tier (1–3), a confidence level and a stance — 40 sources in all (12 Tier-1, 11 Tier-2, 17 Tier-3; stance mix 12 supporting / 12 critical / 16 neutral). Halma is UK-headquartered, so all sources are English-language by design.

Frameworks used

Pyramid-principle executive summary; a Five-Forces read of the niche-instrument markets and the M&A layer; a positioning matrix of the serial-acquirer cohort (acquisition velocity vs. organic compounding); a peer comparables table; and a two-sided case-for/case-against ledger in every analytical section. Frameworks were applied only where the data supported a real conclusion; placements on the positioning map are illustrative analysis, not reported metrics[14][19].

Limitations

• Estimates vs. disclosed figures.The FY26E revenue (~£2.55bn) is the study's own estimate from H1 plus the raised guide, not a company forecast; market cap, P/E, ROE/ROIC and peer figures are point-in-time third-party estimates that move daily[32][15].
• Photonics is not a disclosed segment.The ~19% single-hyperscaler share and the ~55–60% photonics growth come from analyst/secondary reporting, not a standalone Halma segment disclosure[20][22].
• Model critiques are interpretation.The “no Danaher Business System,” “~20-deal ceiling” and “compound at ~10%” points are analyst views (In Practise), not company-confirmed fact[17][19].
• Point-in-time. Figures are as of June 2026 and go stale quickly, especially valuation and the hyperscaler-capex backdrop.

1. [1]Halma — Full Year Results 2024/25Tier 1supportingHigh

   FY2024/25 (year ended 31 March 2025): record revenue £2,248.1m (+11%, +9% organic) and adjusted EBIT £486.3m (+15%), margin 21.6%; 46th consecutive year of dividend growth of ≥5% and 22nd consecutive year of profit growth.

   “Total revenue grew 11% to £2,248.1m... 46th consecutive year of dividend growth of 5% or more... 22nd consecutive year of profit growth.”

2. [2]stockanalysis.com — Halma (LON:HLMA) StatisticsTier 3neutralHigh

   As of early June 2026 Halma's market cap is about £17.6bn, share price ~4,664p, up ~58.5% over 52 weeks; trailing P/E ~51, forward P/E ~39, dividend yield ~0.5%.

   “Market Cap GBP 17.61 billion; Trailing P/E 51.01; Forward P/E 38.82; up 58.53% over the past 52 weeks (as of Jun 5, 2026).”

3. [3]MatrixBCG — Halma growth strategyTier 3neutralMedium

   Halma operates a decentralised serial-acquirer model: 45+ operating companies across 20+ countries acquiring 10-15 niche safety/health/environmental businesses a year.

   “more than 45 businesses across 20+ countries with a decentralised model... acquiring 10–15 businesses annually in Safety, Environmental and Health sectors.”

4. [4]Wikipedia — Halma plcTier 3neutralHigh

   Halma was incorporated in 1894 as The Nahalma Tea Estate Company; pivoted in 1956 to become Halma Investments; listed on the LSE in January 1972; renamed Halma Limited 1973, Halma plc 1981; 1984 Apollo Fire Detectors acquisition moved it into safety; entered FTSE 100 December 2017; HQ Amersham, England.

   “established in 1894 as 'The Nahalma Tea Estate Company Limited'... pivoted dramatically in 1956 to become 'Halma Investments Limited'... The 1984 acquisition of Apollo Fire Detectors marked a strategic move into safety equipment.”

5. [5]Halma — Our historyTier 1neutralHigh

   David Barber co-founded the modern Halma with Mike Arthur, was CEO for over twenty years and Chairman until his retirement in 2003; his 1997 strategy emphasised 'the long term view, aiming from the start to build slowly and carefully'.

   “David Barber co-founded Halma with Mike Arthur; served as CEO for over twenty years and Chairman until 2003... '...the long term view, aiming from the start to build slowly and carefully'.”

6. [6]Halma — appoints Dame Louise Makin as next ChairTier 1neutralHigh

   Marc Ronchetti was appointed Group Chief Executive in 2023, succeeding Andrew Williams (CEO 2005-2023); Dame Louise Makin chairs the board.

   “Dame Louise Makin... non-executive chair of the Halma plc Board of Directors... supported by CEO Marc Ronchetti (appointed 2023).”

7. [7]Wikipedia — Halma plc (figures)Tier 3neutralMedium

   Halma employs approximately 8,000 people (as of 2026); FY2025 net income was £296.4m.

   “Net income: £296.4 million; Employees: approximately 8,000 (as of 2026).”

8. [8]Halma — Who we areTier 1supportingHigh

   Halma reports three market-defined sectors — Safety, Environmental & Analysis, and Healthcare — whose demand is driven by structural megatrends: climate/pollution, rising regulation, demand for healthcare and for life-critical resources.

   “three main reportable segments (Safety, Environmental & Analysis and Healthcare)... resilient, long-term growth drivers: global efforts to address climate change, waste and pollution; increasing regulation; increasing demand for healthcare; and increasing demand on life-critical resources.”

9. [9]Halma — FY2024/25 sector performanceTier 1neutralHigh

   FY2025 sector growth: Environmental & Analysis +18% revenue (+19% organic), adjusted profit +25.4%; Safety +9.5% (+7.7% organic); Healthcare +3.2% (+0.3% organic), adjusted profit +0.3% organic.

   “Environmental & Analysis +18.0% revenue (+19.0% organic)... Safety +9.5%... Healthcare +3.2% (+0.3% organic).”

10. [10]Halma — Investment caseTier 1supportingHigh

    Halma's stated growth model targets roughly 50% organic and 50% acquisitive growth, an ambition to double earnings per share every five years, and KPIs including high ROTIC and a 19-23% EBIT margin band.

    “long-term ambition to double earnings per share every five years... reinvesting in organic development... while simultaneously pursuing acquisitions.”

11. [11]Halma — FY2024/25 capital metricsTier 1supportingHigh

    FY2025 capital metrics: ROTIC 15.0% (+60bps), cash conversion 112%, net debt/EBITDA 0.97x, R&D £108.4m (4.8% of revenue), adjusted EPS 94.23p (+14%), total dividend 23.12p (+7%).

    “ROTIC: 15.0%... Cash Conversion: 112%... Net Debt/EBITDA: 0.97x... R&D Investment: £108.4m (4.8% of revenue)... Adjusted EPS: 94.23p (+14%).”

12. [12]In Practise — Halma, Danaher, Constellation Software & serial acquirer org structuresTier 2neutralMedium

    Halma's long-term Return on Total Invested Capital target is around 12%; each sector aims for ~20%+ net margins, with a historic group ambition of ~16% annual profit-before-tax growth.

    “Aims for 15-20 acquisitions annually with ~20%+ net margins per sector... Growth target: 16% annual PBT increase (50% organic, 50% acquisition-driven).”

13. [13]In Practise — Halma, Judges Scientific, SDI & scaling niche serial acquirersTier 2neutralMedium

    Halma sits among a cluster of high-quality serial acquirers — Constellation Software, Danaher, Diploma, Judges Scientific, Lifco, Addtech — that built 'Swedish-style' niche-acquisition compounders; Diploma is about half Halma's size.

    “Judges Scientific, Diploma, and Halma have each built recognisably Swedish-style models in British markets, focused on niche industrial and scientific businesses with high recurring revenue and low customer concentration.”

14. [14]In Practise — serial acquirer org structures (peers)Tier 2criticalMedium

    Constellation Software has scaled to ~100 acquisitions a year by pushing M&A down to operating units; Danaher is far larger and uses the Danaher Business System to drive post-acquisition improvement — a systematic capability Halma is said to lack.

    “Danaher uses the Danaher Business System (DBS)... Halma lacks an equivalent 'rigorous, group-wide culture' focused on relentless operational improvement... CSU has scaled to ~100 acquisitions annually by pushing M&A duties down to operating units.”

15. [15]GuruFocus / peer valuation comparisonTier 3criticalMedium

    Valuation comparison (mid-2026): Halma forward P/E ~39x, Diploma ~28x, Danaher ~24x, Honeywell ~20-21x; Halma carries the highest multiple in the peer set.

    “Halma forward P/E ~39.5x (2026); Diploma ~28.13x; Danaher ~24.33x; Honeywell ~20-21x.”

16. [16]In Practise — Halma acquisition criteria & modelTier 2supportingMedium

    Halma's edge is described as buying niche, highly-engineered businesses with strong positions in small markets and preserving local management autonomy ('startup agility with multinational scale'), historically paying ~8x EBIT (2003-2013).

    “Targets niche, highly-engineered industrial/medical products dominating small markets... Historically paid ~8x EBIT (2003-2013)... Operating companies retain significant autonomy and entrepreneurial culture.”

17. [17]In Practise — risks of Halma's modelTier 2criticalMedium

    Critics argue Halma's model faces scalability limits: moving from a pure 'accumulator' toward a 'platform' with sector layers can remove full opco P&L ownership and dull incentives; without a DBS-style improvement system it leans heavily on the quality of assets bought on day one.

    “eliminating full P&L responsibility for opco leaders 'may create perverse incentives by reducing the agency of those running the operating company'... the company must rely heavily on 'quality of assets purchased on day 1' rather than transformation capability.”

18. [18]In Practise — Halma long-term track recordTier 2supportingMedium

    Reported 20-year free-cash-flow CAGR of ~15% and a multi-decade dividend per share CAGR of ~5% support the durability of Halma's compounding model.

    “20-year FCF CAGR of 15%, 33-year dividend CAGR of 5%.”

19. [19]In Practise — scaling limitsTier 2criticalMedium

    Some analysts note the In Practise thesis that most serial acquirers never break 20 deals a year, implying Halma may 'compound FCF at ~10% per year' rather than match Constellation-level returns absent organisational change.

    “Halma will likely 'compound FCF at 10% per year' rather than match CSU-level returns, as 'most acquirers never break the 20 acquisitions per year level'.”

20. [20]Proactive — Halma surges on AI-linked demandTier 2neutralHigh

    In H1 FY2025/26 a single hyperscaler customer accounted for 19% of group revenue (up from 14% a year earlier), driven by Avo Photonics demand for AI-data-centre optical components; photonics added ~8 percentage points to group organic growth, growing ~55-60% organically.

    “A single hyperscaler customer represented 19% of group revenue in H1 (up from 14% year-ago), driven by Avo Photonics demand... Photonics contributed approximately 8 percentage points to group organic revenue growth, expanding at roughly 60% organically.”

21. [21]Proactive — analyst commentary (UBS, Stifel)Tier 2supportingHigh

    UBS and Stifel argued the H1 FY2026 beat was 'not just a photonics story': Environmental & Analysis excluding photonics grew ~18% organically; Healthcare +7%; Safety +6%. UBS raised its target to 4,100p; Stifel called the ~31x FY2026 multiple 'full' but justified by the performance.

    “UBS: 'not just a photonics story'... E&A excluding photonics grew circa 18% organically... Stifel noted the valuation as 'full' at 31x FY2026 earnings but defended the premium: 'this kind of performance fully justifies a substantial premium.'”

22. [22]Crack the Market — The European Photonics SupercycleTier 3criticalMedium

    Halma's Avo Photonics has a ~10-year relationship with one undisclosed hyperscaler, supplying optical engines / silicon-photonics components; the position scaled to ~19-20% of group sales — a concentration that warrants investor attention.

    “Avo Photonics has a ten-year relationship with one undisclosed hyperscaler customer... a long-standing single-hyperscaler relationship that has scaled to 20% of Halma group sales.”

23. [23]Investing.com — Halma lifts guidance after record H1 FY2026Tier 2supportingHigh

    H1 FY2025/26 (six months to 30 Sept 2025): record revenue £1,237.4m (+15.2%, +16.7% organic), adjusted EBIT £282.0m (+26.7%), margin 22.8% (+210bps), adjusted PBT £270.5m (+29.3%), statutory PBT £241.8m (+39.0%), interim dividend 9.63p (+7%); ROTIC 16.2%, net debt/EBITDA 1.03x; FY2026 organic growth guidance raised to mid-teens.

    “H1 revenue: £1.24 billion, up 15.2%; 16.7% organic... Adjusted EBIT £282.0m, up 26.7%; margin 22.8%... Statutory PBT £241.8m, up 39.0%... Revised FY2026 guidance: mid-teens organic constant-currency revenue growth.”

24. [24]Halma — Half Year Results 2025/26Tier 1supportingHigh

    Halma shares rose ~10% on the day of the November 2025 H1 results and guidance upgrade; the stock was up ~58.5% over the prior 52 weeks by early June 2026.

    “Record first-half performance with Revenue and Adjusted profit growth in all sectors; margin increased in all sectors.”

25. [25]Halma — FY2024/25 M&A activityTier 1neutralHigh

    FY2025 M&A: seven acquisitions completed for up to £157m maximum consideration; in H1 FY2026 two acquisitions deployed £129m.

    “Seven acquisitions completed for £157m maximum consideration.”

26. [26]stockanalysis.com — Danaher statisticsTier 3neutralMedium

    Danaher reported 2025 quarterly revenue around $5.9bn (Q2), with full-year core revenue growth ~3% — a far larger but lower-growth comparator to Halma; Danaher trades around 24x forward earnings.

    “Danaher expects non-GAAP core revenue to grow approximately 3%... Q2 2025 revenues increased 3.5% year-over-year to $5.9 billion.”

27. [27]In Practise — Judges Scientific & niche serial acquirersTier 2neutralMedium

    Judges Scientific (niche scientific-instrument serial acquirer) has returned roughly 100x since 2006 on a strict 3-6x EBIT acquisition discipline — a smaller, cheaper-buying comparator to Halma; analysts flag both Judges and SDI face scaling hurdles beyond ~25 companies.

    “Judges Scientific alone has returned roughly 100 times its value since 2006... global scientific instrument leaders in niche markets... a valuation of 3-6x EBIT.”

28. [28]Proactive — Halma half-year update fails to impress market (Healthcare destocking, weak China)Tier 2criticalMedium

    Halma has been through softer trading periods: a half-year update where weaker Healthcare trading amid customer destocking and weak China meant the print failed to impress the market — evidence the model is not immune to destocking and end-market cycles.

    “Stronger revenue growth in the Safety and Environmental & Analysis sectors offset weaker trading in the Healthcare sector amid customer destocking.”

29. [29]Alpha Spread — Halma intrinsic valuationTier 3criticalMedium

    Skeptics argue Halma is richly valued: independent analyses have called it overvalued versus intrinsic value, with a forward P/E around or above 39x — well above the FTSE 100 average and above peers — leaving little room if growth normalises to high-single digits.

    “one analysis indicating it is overvalued by 32% compared to its intrinsic value... forward P/E multiple is now 40.37x.”

30. [30]TipRanks — cautious outlook / Sell rating on HalmaTier 3criticalMedium

    A broker issued a Sell on Halma citing high valuation and the Brownline acquisition being at the top of Halma's typical price range with strategic-fit questions (horizontal gas drilling vs. its renewable/clean-energy focus).

    “Sell Rating Due to High Valuation and Strategic Misalignment in Brownline Acquisition... valued at the higher end of Halma's typical acquisition range.”

31. [31]International Fire & Safety Journal — Halma acquires E2S for £230mTier 2neutralHigh

    Halma's December 2025 acquisition of E2S Group (industrial warning-signal devices, ~£44m revenue) for £230m / ~$307m is reported as a notably large deal versus its historic bolt-on average of ~4.8 deals a year, signalling a shift toward larger acquisitions.

    “Halma acquires E2S in £230m move into industrial safety... E2S revenue for the 12 months to 31 December 2025 is forecast to be approximately £44m.”

32. [32]stockanalysis.com — Halma TTM financialsTier 3neutralMedium

    Over the trailing twelve months to early June 2026 Halma generated revenue of about £2.41bn and net income of about £347m; ROE ~18.6%, ROIC ~14.3%.

    “Revenue: GBP 2.41 billion; Net Income: GBP 347.00 million; Return on Equity (ROE): 18.61%; ROIC: 14.28%.”

33. [33]stockanalysis.com — Diploma statisticsTier 3neutralMedium

    Diploma plc, a comparable UK serial acquirer about half Halma's size, trades around 28x forward earnings with a Buy consensus; Spectris (a UK instrumentation peer) agreed a recommended cash takeover by Advent in 2025 — illustrating both peer demand and consolidation in the niche-instrument space.

    “Diploma is... about half the size of Halma... forward PE ratio is 28.13... Spectris: board reached agreement on the terms for a recommended cash acquisition by Advent (June 2025).”

34. [34]MatrixBCG — Halma acquisition historyTier 3neutralMedium

    Halma has completed roughly 150+ acquisitions over its history (one count cites 154 since 1983) with a dedicated M&A team of 20+ specialists, integral to its 50% acquisition-driven growth.

    “Since 1983, Halma has completed 154 acquisitions and has a team of over 20 dedicated M&A specialists.”

35. [35]TIKR — How Halma's long-term trends shape its path into 2026Tier 3supportingMedium

    Halma frames its three sectors around long-run megatrends — urbanisation, ageing populations, tightening environmental regulation and demand on life-critical resources — that it argues make demand resilient across cycles.

    “long-term megatrends such as urbanization, aging populations and increased environmental regulation... structural drivers support demand for its technologies.”

36. [36]Crack the Market — hyperscaler capex backdropTier 3neutralMedium

    Hyperscaler capex is the backdrop to Halma's photonics surge: Alphabet, Amazon, Meta and Microsoft collectively invested ~US$350bn in 2025, forecast to rise toward ~US$575bn in 2026 (+64%), as AI data centres shift interconnects from copper to optics.

    “Four of the largest North American-based hyperscalers... collectively invested approximately US$350 billion in FY 2025... forecasts indicating an increase to ~US$575 billion in FY 2026 (+64% year-on-year).”

37. [37]Investing.com — FY2026 guidance raisedTier 2supportingHigh

    FY2026 guidance was raised at the half-year to mid-teens organic constant-currency revenue growth with adjusted EBIT margin ~22%, after the initial FY2026 guide of upper-single-digit organic growth set in the FY2025 results.

    “Revised FY2026 guidance: mid-teens percentage organic constant-currency revenue growth... FY2026 adjusted EBIT margin guidance: approximately 22%.”

38. [38]Halma — purpose statementTier 1neutralHigh

    Halma describes its purpose as 'growing a safer, cleaner, healthier future for everyone, every day', the framing it uses to unify its three sectors and acquisition criteria.

    “Halma's stated purpose is to 'grow a safer, cleaner, healthier future for everyone, every day.'”

39. [39]Halma — Healthcare sector FY2025Tier 1criticalHigh

    Healthcare has been Halma's weakest sector — FY2025 organic revenue and profit growth of just +0.3% — a reminder that not every part of the portfolio compounds evenly and that integration/end-market risk is real.

    “Healthcare +3.2% revenue (+0.3% organic)... Adjusted Profit Growth +4.0% (+0.3% organic).”

40. [40]In Practise — scaling vs ConstellationTier 2criticalMedium

    Across the serial-acquirer cohort, analysts argue Constellation Software's unit economics and capital deployment are hard to replicate; 'incredible businesses' like Halma and Diploma 'can't manage to scale with the same unit economics, returns, and capital as Constellation'.

    “Companies like Halma and Diploma, which are incredible businesses and have been phenomenal investments, can't manage to scale with the same unit economics, returns, and capital as Constellation.”